Wall Street Zen upgraded shares of Achieve Life Sciences (NASDAQ:QUIT – Free Report) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.
QUIT has been the topic of several other research reports. Zacks Research initiated coverage on shares of Achieve Life Sciences in a report on Tuesday, November 10th. They issued a “hold” rating on the stock. Weiss Ratings began coverage on Achieve Life Sciences in a report on Wednesday, November 11th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.
View Our Latest Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
QUIT opened at $6.06 on Friday. Achieve Life Sciences has a twelve month low of $2.62 and a twelve month high of $8.64. The company has a current ratio of 10.49, a quick ratio of 0.95 and a debt-to-equity ratio of 0.03.
About Achieve Life Sciences
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.
See Also
- Five stocks we like better than Achieve Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
